Troferit

Dropropizine

Method of action: Cough And Cold Preparations

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Troferit

This introductory section provides a factual definition of the medication Troferit, focusing on its composition, type, and general mechanism.

Property	Description
Active Ingredient	Dropropizine (INN)
Form	Syrup, Tablets, Oral solution
Pharmacological Class	Non-opioid Antitussive Agent
Common Use	Symptomatic relief of non-productive (dry) cough
Origin	Synthetic

What Type of Medicine is Troferit?

Troferit is a brand name for a synthetic non-opioid antitussive agent containing the active ingredient Dropropizine (Dipropizine), intended to suppress the impulse to cough. The core component is a chemically synthesized small molecule that exists as a racemic compound. Its function places it within the high-level pharmacological class of cough suppressants, distinguishing it structurally from treatments that primarily address congestion or mucus production. It is typically supplied as a single active ingredient product, focusing its therapeutic action exclusively on the cough reflex.

How Does Troferit Differ from Traditional Cough Suppressants?

Unlike narcotic antitussives, Troferit is a peripherally acting medication that achieves its effect by targeting the sensory nerve endings in the respiratory tract. This means it dampens the cough reflex signal at its source in the airways, rather than operating on the cough control center in the brain. This peripheral mechanism allows for a reduction in cough frequency without the central depressant action often associated with codeine. Its classification as non-opioid and non-CNS (non-central nervous system) acting is critical, as it provides symptomatic relief of dry, non-productive coughs while minimizing the risks of dependence and central sedative effects.

In What Forms is Dropropizine Available?

The drug entity Dropropizine is available for oral ingestion in several common dosage forms to accommodate patient preference and age groups. Patients typically encounter Troferit as a liquid, available as a syrup or oral solution, and as solid tablets. The availability of both liquid and solid preparations ensures flexibility, simplifying the administration and measurement of the medication for a broad range of patients.

What side effects are possible with Troferit?

Possible Side Effects and Safety Information

The safety profile of Troferit (Dropropizine) is categorized according to the frequency and body system affected, as documented in official government regulatory labeling. The most frequent adverse reactions are generally non-severe and consistent with the medicine's peripheral action.

Frequency-Classified Adverse Reactions

The officially listed side effects are categorized based on their documented incidence:

Common Reactions (Occur in 1 to 10 users out of 100): These effects primarily involve the Gastrointestinal and Nervous Systems. They include drowsiness (somnolence), dizziness, nausea, vomiting, dyspepsia, and abdominal pain.
Uncommon Reactions (Occur in 1 to 10 users out of 1,000): These are less frequent, primarily manifesting as allergic skin reactions, such as urticaria (hives) or erythema (skin redness).
Rare Reactions (Occur in 1 to 10 users out of 10,000): Fatigue or malaise may occur.

Safety Constraints and Special Populations

Official prescribing information includes specific limitations regarding the medicine's use:

Severe Adverse Reactions: Hypersensitivity reactions, including rare occurrences of anaphylactic shock or anaphylactoid reactions, are documented safety concerns.
Time-Related Patterns: Effects like drowsiness and dizziness may be more likely to appear at the beginning of treatment.
Absolute Contraindications: The medicine is formally contraindicated in patients with severe renal impairment or severe hepatic impairment. It is also contraindicated during pregnancy and lactation due to insufficient safety data. Furthermore, it should not be used in individuals with bronchial hypersecretion or impaired mucociliary function.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below outlines the officially documented presentation and required actions for acute over-exposure to Troferit (Dropropizine), as stated in government regulatory sources.

Documented Overdose Manifestations

Overdose manifestations are generally extensions of the drug's known effects, presenting as somnolence (drowsiness), dizziness, faintness, and gastrointestinal disturbances such as nausea or diarrhea. In severe acute over-exposure, the regulatory documentation notes the potential for clouding of consciousness (stupor).

Critical Systems and Management

Regulatory documents specify that management of an overdose requires special attention to cardiac, respiratory, renal, and hepatic functions, indicating these systems are the focus of risk assessment. The official position states that no specific antidote is known for the management of overdosage with Dropropizine.

When to Seek Immediate Medical Attention

Any suspected acute over-exposure to Troferit requires immediate medical attention. This is necessary because the required treatment is symptomatic and supportive, meaning a healthcare professional must provide continuous monitoring and supportive therapies for the critical physiological systems potentially affected.

Therapeutic Uses of Troferit

What Troferit Treats: Main Uses and Benefits

Troferit (Dropropizine) is commonly used to help with targeted symptomatic relief for specific, distressing respiratory manifestations. It is relevant when supportive symptom management is appropriate to ease the burden of intense, frequent symptoms. The medication's therapeutic function is the symptomatic relief of cough.

This medication helps address symptom clusters that may become intense or disruptive, specifically the irritating, non-productive cough associated with conditions characterized by periods of heightened symptoms, such as acute upper respiratory infections and acute bronchitis. It is generally applied in contexts marked by increased discomfort where coughs are characterized by a hacking or persistent sensation without phlegm.

The key therapeutic benefit helps ease the overall symptom burden of persistent coughing, which may assist patients to cope more steadily with difficult episodes. It is relevant in the clinical scenario of nighttime cough, where its use contributes to easing discomfort and supports general well-being during symptomatic periods, which may assist with maintaining functional stability.

“It is commonly used to provide symptomatic support when the cough is dry and interferes with rest.”

Quick Fact: Symptom Management for Irritating Non-Productive Cough The medication is relevant for managing symptoms that interfere with daily comfort, particularly when the cough is dry, persistent, and without mucus.

Regulatory References

FDA Verification Portal

Eligibility and Restrictions for Use

Who Can and Cannot Use Troferit?

The eligibility for Troferit (Dropropizine) is determined by official regulatory documents based on age, organ function, and specific underlying conditions. The eligible population primarily consists of adults and children over 2 years of age with a non-productive cough.

Absolute Contraindications

Troferit is strictly contraindicated and must not be used by patients who have a known hypersensitivity to the drug or any of its components. Use is also prohibited for individuals with severe liver impairment. The medicine is contraindicated for patients experiencing conditions involving excessive mucus discharge or limited mucociliary function (e.g., primary ciliary dyskinesia).

Age and Conditional Restrictions

Regulatory rules establish specific limitations for age groups and physiological states. The medicine is not established and therefore not recommended for children under 2 years of age.

Conditional use is required for patients with serious renal insufficiency, where the medicine should be administered with caution. Furthermore, use is generally not recommended during pregnancy or lactation due to insufficient data regarding safety in these physiological states. Older adults should also be treated with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Troferit (Dropropizine) possesses an official interaction profile focused on potential pharmacodynamic reinforcement with other substances. Authoritative regulatory agencies classify its interaction profile as primarily use-with-caution, as no combinations are formally listed as contraindicated due to interaction risk.

Regulatory documents do not detail interactions involving metabolic enzymes (such as CYP450) or drug transporters. The documented interaction is centered on the potential for additive central nervous system (CNS) depression when co-administered with certain agents.

Interacting Substance/Class	Official Interaction Statement
Sedative Drugs	Co-administration requires documented care due to potential additive pharmacodynamic effects, resulting in enhanced symptoms such as drowsiness or somnolence.
Alcohol	Caution is advised against concurrent use, as alcohol may augment the overall sedative effects of the medicine.
Sensitive Individuals	The caution regarding the additive sedative effect is specifically noted for co-administration with sedative drugs in sensitive individuals.

Specific regulatory studies have noted no interaction with Benzodiazepines during trials; however, these agents remain within the broader class-based warning for sedative drugs. The regulatory profile is concerned with managing the risk of enhanced sedation and does not impose any mandatory dose timing or separation requirements.

Mechanism of Action

Selective Receptor Modulation

Troferit engages with specific GABA-A receptor subtypes as a positive allosteric modulator, selectively enhancing the natural inhibitory effect of the GABA neurotransmitter. This action modifies early molecular steps at the receptor level, altering the threshold for excitation, and influencing the frequency of neuronal signaling events.

Central and Peripheral Signaling Dampening

The mechanism directly affects the GABAergic inhibitory pathway, a crucial system for modulating neuronal excitability in both the spinal cord and subcortical brain regions. By increasing chloride ion conductance into the neuron, the drug enhances the inhibitory potential against electrical mediator activity. This focused action is relevant in systems characterized by high levels of excitatory signaling, resulting in a measurable alteration in overall neuronal excitability and shaping the drug's physiological effect profile.

Dosage and Administration Information

Troferit (Dropropizine) is administered exclusively through the oral route in all its available dosage forms, including tablets and syrup. Use is limited to short-term symptomatic therapy, with established parameters for dosing, frequency, and duration.

Parameter	Guideline
Route of Administration	Oral use only.
Adult Dosing Regimen	60 mg per dose for individuals 12 years and older. The maximum total daily dose is limited to 180 mg.
Dosing Frequency	Administered up to three times daily, requiring a minimum 6-hour interval between administrations to prevent accumulation.
Duration of Use	The treatment period must not exceed seven days and should be stopped immediately upon resolution of the cough.
Timing	Must be taken between meals (away from food).

Administration for Specific Populations

Administration in the pediatric population (over 2 years of age) requires a specific, weight-based calculation: 1 mg per kilogram of body weight per dose. For liquid formulations, accurate measurement using a calibrated dosing device is required for proper administration. Clinical guidelines indicate that use in older adults or patients with severe renal or hepatic impairment should be considered with caution, reflecting the need for careful review in these populations. The syrup formulation is noted to contain sucrose, which is an important administrative detail for patients managing carbohydrate intake.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Troferit

This overview summarizes the available clinical evaluation of Troferit (Dropropizine), focusing on the types of research conducted, the outcomes studied, and the acknowledged gaps in the evidence. This information is purely descriptive and does not offer clinical advice or instruction.

Evidence for Use in Symptomatic Relief of Non-Productive (Dry) Cough

Research examining conditions characterized by outcomes related to physical discomfort (dry, non-productive cough) primarily relies on Randomized Controlled Trials (RCTs) and subsequent meta-analyses. These studies were applied in research examining patient-reported experiences related to cough intensity and frequency.

Researchers monitored several key outcomes, including the measurement of cough frequency (the number of coughing episodes) during the day and during the night. Trials also examined outcomes reflecting daily functioning, such as the incidence of nocturnal awakenings caused by coughing. Findings describe patterns observed in the studies related to symptom variability over the short-term observation period.

Short-Term Findings and Comparator Study Focus

The majority of primary trials for Dropropizine were conducted during periods of increased symptom activity and were relevant in trials assessing short-term or episodic symptom patterns, with follow-up durations that were limited, often to a period of three to seven days. Research has explored short-term changes observed during these defined time intervals.

Dropropizine (the racemic compound) was evaluated in studies where it was often compared against its single active isomer, Levodropropizine. Research describes patterns related to differences in observed outcomes between the two forms. These comparative studies, which contribute to the broader evidence landscape, typically focused on how data show patterns related to central nervous system effects, such as somnolence.

Evidence in Special Populations

Clinical evidence for Troferit was studied for use in distinct demographic groups. Early comparative trials and meta-analyses research examined populations of children (pediatric patients) with non-productive coughs, often in the 2 to 14 years age range. These studies monitored how patient-reported outcomes describing perceived discomfort were measured in this group.

What Remains Uncertain About Troferit

While research was studied for outcomes related to physical discomfort and acute, short-term cough symptoms, long-term effects are not fully established. There is limited information available concerning outcomes following repeated or extended use of the drug beyond the few days typically covered in the primary clinical trials.

Frequently Asked Questions (FAQ)

Common questions about Troferit (FAQ)

Q: Why does the packaging for Troferit contain a warning about driving?

Official labeling for Troferit addresses the potential for effects that may impair attention. According to the official product information, the medicine can cause certain side effects, such as drowsiness (feeling sleepy) and dizziness. These nervous system effects are why a warning is present regarding the ability to drive or safely operate complex machinery.

Q: Does Troferit require any specific monitoring or regular tests?

Regulatory documents indicate that caution is advised when Troferit is used by patients who have existing severe renal (kidney) or hepatic (liver) impairment. This caution reflects the need for careful review of usage in these populations, as noted in regulatory guidance.

Q: What does the term 'contraindication' mean for Troferit?

In the context of Troferit, a contraindication is a specific condition or circumstance that officially prohibits the use of the medicine. Regulatory documents state that when a contraindication is present (such as severe liver impairment or pregnancy), using the medicine is considered potentially harmful or officially not allowed.

How should Troferit be stored and disposed of?

How to Store and Dispose of Troferit?

Official regulatory documents define specific storage and disposal requirements for Troferit (Dropropizine) to ensure stability and public safety.

Storage Conditions

Requirement	Constraint
Temperature	Do not store above 30 C.
Environment	Keep in a cool, dry, well-ventilated place, protected from light and moisture.
Container	Store in the original receptacle with the cap tightly closed.
Child Safety	Must be stored out of the sight and reach of children.
Post-Opening Stability	Liquid formulations must be discarded after 1 month of opening.

Disposal Instructions

Unused or expired medicine should be taken to an authorized drug take-back location. If this option is unavailable, the medicine must be removed from its original container, mixed with an unappealing substance (like dirt or coffee grounds), and placed in a sealed bag before being disposed of in the household trash. Do not flush Troferit down the toilet or pour it down the sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.